A move by Roche and its newly acquired subsidiary Genentech to kill a trio of development pacts within just a few days has triggered some deep-seated fears that the pharma giant is winnowing out programs from its combined pipeline, according to a report in the San Francisco Business Times. Roche and Genentech are engaged in a wide range of pacts that pump millions of dollars into their partners' coffers. But the two companies insist that the rapid-fire execution of deals is not connected to any kind of new review process triggered by the merger. "Nothing's changed," a Genentech spokesperson told the weekly. "We're going over the same review process we've always had." Report